|Back to main|
Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most
12/16/2011 5:38:00 PM
(Written by Rebecca Lipman. Institutional data sourced from Fidelity.)
Covidien Plc (COV) plans to spin off its pharmaceuticals division from its surgical products in order to create a separate company better able to compete in the growing pain-management area, reports Bloomberg.
The drug unit alone generates about $2 billion in annual sales compared to the company’s medical products business, which has annual sales of about $9.6 billion. It will take an estimated 18 months for the spin-off to be complete.
“The pharma division has been a drag on the company’s top-line growth rate,” said Joanne Wuensch of BMO Capital Markets in a note. The spinoff “should provide a relief to the overhang and questions that have dogged this division.”
The market reacted favorably to the news, jumping 3.3% on Thursday – a nice rebound from the 7.7% drop this year prior to the announcement.
One of Many
Covidien’s spinoff follows a recent trend among health-care companies who have shed their weaker links in order to grow their core operations.
This isn’t the first spin-off for Covidien either – the company recently divested three business units. In December of 2009 it sold its U.S. radiopharmaceutical business to Parthenon Capital LLC. It also made two deals in 2010 to sell units to New Mountain Capital LLC, based in New York.
Covidien’s pharmaceutical product lines include Exalgo, a 24-hour extended release opioid, and Pennsaid, a topical anti- inflammatory medication. Perhaps these drugs will be more profitable in a company focused on their marketing and development.
So we were wondering what pharmaceutical companies are seeing positive attention from hedge funds as they are now, including deals already in the pipeline.
To find out, we created a list of major drug companies and screened them for the names seeing the highest levels of institutional buying. The “smart money” thinks these drug companies have more upside than downside.
Do you agree?
Analyze These Ideas (Tools Will Open In A New Window)